Biogen Inc. (BIIB): R&D Expense
$1.78B
Year ended 2025-12-31
$1.88B
Trailing 12 months to 2026-03-31
-7.3%
3-year compound annual growth
-14.9%
5-year compound annual growth
-1.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.78B | -10.2% | 2026-02-06, From 2025-01-01 |
| 2024-12-31 | $1.98B | -19.0% | 2026-02-06, From 2024-01-01 |
| 2023-12-31 | $2.45B | +9.6% | 2026-02-06, From 2023-01-01 |
| 2022-12-31 | $2.23B | -10.8% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $2.50B | -37.3% | 2024-02-14, From 2021-01-01 |
| 2020-12-31 | $3.99B | +75.0% | 2023-02-15, From 2020-01-01 |
| 2019-12-31 | $2.28B | -12.2% | 2022-02-03, From 2019-01-01 |
| 2018-12-31 | $2.60B | +15.2% | 2021-02-03, From 2018-01-01 |
| 2017-12-31 | $2.25B | +14.2% | 2020-02-06, From 2017-01-01 |
| 2016-12-31 | $1.97B | -2.0% | 2019-02-06, From 2016-01-01 |
| 2015-12-31 | $2.01B | +6.3% | 2018-02-01, From 2015-01-01 |
| 2014-12-31 | $1.89B | +31.1% | 2017-02-02, From 2014-01-01 |
| 2013-12-31 | $1.44B | +8.2% | 2016-02-03, From 2013-01-01 |
| 2012-12-31 | $1.33B | +9.5% | 2015-02-04, From 2012-01-01 |
| 2011-12-31 | $1.22B | -2.3% | 2014-02-06, From 2011-01-01 |
| 2010-12-31 | $1.25B | -2.7% | 2013-02-05, From 2010-01-01 |
| 2009-12-31 | $1.28B | +19.7% | 2012-02-03, From 2009-01-01 |
| 2008-12-31 | $1.07B | +15.9% | 2011-02-04, From 2008-01-01 |
| 2007-12-31 | $925.16M | n/a | 2010-02-09, From 2007-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $5.80B | -1.8% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.02B | +38.9% |
| Amgen Inc (AMGN) | 2025-12-31 | $7.27B | +21.9% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $825.00M | -9.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $187.52M | -3.1% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.13B | -31.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $81.49M | +3.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
Compare BIIB, GILD, NBIX, AMGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗